Blauvelt, A. , Rich, P., Sofen, H., Lambert, J., Merola, J., Lebwohl, M., Hippeli, L., Kisa, R., Banerjee, S. and Kimball, A. 2022. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials. SKIN The Journal of Cutaneous Medicine. 6, 4 (Jul. 2022), s41. DOI:https://doi.org/10.25251/skin.6.supp.41.